Another BET inhibitor, ABBV-744, that is being investigated in clinical trials for relapsed/refractory acute myeloid leukemia (AML) as well as myelofibrosis (NCT03360006, NCT04454658) has shown promising results in prostate cancer models [16]. Here, DNER is linked to prostate cancer.